Key Portfolio Assets
Partner | Asset Name | Target | Royalty Rate | |||
---|---|---|---|---|---|---|
Alora Pharmaceuticals | DSUVIA® | Acute pain | 15-75% | clinical trials | news | asset website |
AVEO Oncology | ficlatuzumab (AV-299) | HGF | Low single-digit | clinical trials | news | posters, presentations |
Day One | tovorafenib (DAY101) | pan-RAF | Mid-single-digit | clinical trials | news | posters, presentations |
Janssen Biotech | cetrelimab (JNJ-63723283) | PD-1 | 0.75% | clinical trials | news | posters, presentations |
Medexus | IXINITY | Factor IX | Mid-single-digit | news | asset website | |
Rezolute | RZ358 | INSR | High single-digit to mid-teens | clinical trials | news | posters, presentations |
Roche | faricimab | angiopoietin-2 and VEGF-A | 0.5% | clinical trials | news | posters, presentations |
Takeda | mezagitamab (TAK-079) | CD-38 | 4% | clinical trials | news | posters, presentations |
Zevra | arimoclomol | heat-shock protein amplifier | mid-single-digit | clinical trials | news | posters, presentations |
Large Pharma Assets
Partner | Asset Name | Target | Royalty Rate | |||
---|---|---|---|---|---|---|
AstraZeneca | rilvegostomig (AZ2396) | TIGIT/PD-1 | undisclosed | clinical trials | news | posters, presentations |
Bayer | BAY1831865 | Factor XIa | Low single-digit | news | ||
Janssen Biotech | JNJ-63898081 | PSMAxCD3 | 0.75% | clinical trials | news | |
Janssen Biotech | Undisclosed | GPRC5DxCD3 | 0.75% | |||
Janssen Biotech | JNJ-63709178 | CD123xCD3 | 0.75% | clinical trials | news | |
Merck | MK-4830 | ILT-4 | Low single-digit | clinical trials | news | posters, presentations |
Novartis | iscalimab (CFZ533) | CD-40 | Mid-single-digit to low teens | clinical trials | news | posters, presentations |
Novartis | gevokizumab (VPM087) | IL-1ß | High single-digit to mid-teens | clinical trials | news | posters, presentations |
Novartis | NIR178 | adenosine A2A | Low single-digit | clinical trials | news | posters, presentations |
Regeneron | vidutolimod (CMP-001) | TLR9 | High single-digit to double digit | clinical trials | news | posters, presentations |
Biotech Assets
Partner | Asset Name | Target | Royalty Rate | |||
---|---|---|---|---|---|---|
Affimed | acimtamig (AFM13) | CD30/CD16A | Undisclosed | clinical trials | news | posters, presentations |
Affimed | AFM24 | EGFR/CD16A | Undisclosed | clinical trials | news | posters, presentations |
Agenus | INCAGN01949 | OX-40 | Mid-single-digit | clinical trials | news | |
Aronora | gruticibart (AB023) | Factor XI | Low single-digit | clinical trials | news | posters, presentations |
Aronora | E-WE thrombin (AB002) | E-WE thrombin | Low single-digit | clinical trials | news | posters, presentations |
Aronora | AB054 | Factor XII | Low single-digit | news | posters, presentations | |
Compugen | COM902 | TIGIT | undisclosed | clinical trials | news | posters, presentations |
Denovo Biopharma | vosaroxin | topoisomerase II | high single-digit | clinical trials | news | posters, presentations |
ImmunityBio | aldoxorubicin | albumin-linked formulation of doxorubicin | mid-single-digits to mid-teens | clinical trials | news | posters, presentations |
Incyte | INCAGN01876 | GITR | Mid-single-digit | clinical trials | news | |
Incyte | INCAGN02385 | LAG-3 | Low to mid-single-digit | clinical trials | news | |
Incyte | INCAGN02390 | TIM-3 | Low to mid-single-digit | clinical trials | news | |
Molecular Templates | MT-0169 | CD-38 | 4% | clinical trials | news | posters, presentations |
Monopar Therapeutics | MNPR-101 | uPAR | None | news | posters, presentations | |
Palobiofarma | PBF-680 | adenosine A1 | Low single-digit | clinical trials | news | posters, presentations |
Palobiofarma | PBF-677 | adenosine A3 | Low single-digit | clinical trials | news | posters, presentations |
Palobiofarma | PBF-999 | adenosine A2A / Phosphodiesterase 10 (PDE-10) | Low single-digit | clinical trials | news | posters, presentations |
Palobiofarma | PBF-1129 | adenosine A2B | Low single-digit | clinical trials | news | posters, presentations |
Palobiofarma | PBF-1650 | adenosine A3 | Low single-digit | clinical trials | news | posters, presentations |
Resilience | NTM-1632 | Botulinum neurotoxins | 15% | clinical trials | news | posters, presentations |
Resilience | NTM-1633 | Botulinum neurotoxins | 15% | clinical trials | news | posters, presentations |
Resilience | NTM-1634 | Botulinum neurotoxins | 15% | clinical trials | news | posters, presentations |
Resilience | NTM-1631 | Botulinum neurotoxins | 15% | clinical trials | news | posters, presentations |
Rezolute | AB101 | Injectable basal insulin | Low single-digit | news | posters, presentations | |
Rezolute | RZ402 | Kallikrein inhibitor | Low single-digit | clinical trials | news | posters, presentations |